Article
Humoral immune responses to EGFR-derived peptides predict progression-free and overall survival of non-small cell lung cancer patients receiving gefitinib.
PloS one - 1 Jan 2014
Azuma Koichi, Komatsu Nobukazu, Hattori Satoshi, Matsueda Satoko, Kawahara Akihiko, Sasada Tetsuro, Itoh Kyogo, Hoshino Tomoaki
Abstract excerpt
Somatic mutations in the epidermal growth factor receptor (EGFR) gene are associated with clinical response to EGFR tyrosine kinase inhibitors (TKIs), such as gefitinib, in patients with non-small cell lung cancer (NSCLC). However, humoral immune responses to EGFR in NSCLC patients have not been...
Topics
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Agents
- Carcinoma, Non-Small-Cell Lung
- Disease-Free Survival
- ErbB Receptors
- Exons
- Female
- Gefitinib
- Humans
- Immunity, Humoral
- Immunoglobulin G
- Kaplan-Meier Estimate